Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13459877 | 0.75 | CYP1A2 (0.32) | — | |
| SCHEMBL3155087 | 0.74 | CTNNB1 (0.31) | CTNNB1WNT3A | |
| SCHEMBL2797568 | 0.73 | ALDH1A1 (0.39) | — | |
| SCHEMBL29955238 | 0.73 | ALDH1A1 (0.39) | — | |
| SCHEMBL585779 | 0.72 | — | — | |
| SCHEMBL15969130 | 0.70 | ALDH1A1 (0.49) | CTNNB1WNT3A | |
| SCHEMBL29957430 | 0.69 | GRM1 (0.37) | CTNNB1WNT3A | |
| SCHEMBL21382866 | 0.68 | ALDH1A1 (0.50) | CTNNB1WNT3A | |
| SCHEMBL578979 | 0.68 | CTNNB1 (0.36) | CTNNB1WNT3A | |
| SCHEMBL578818 | 0.68 | CTNNB1 (0.36) | CTNNB1WNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2136807-B1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE DERIVATIVES FOR TREATING TUBERCULOSIS | GLAXO GROUP LTD (GB) | 2010-11-03 | — | — | EP | disclosed |
| US-20100048544-A1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE-DERIVATIVES FOR TREATING TUBERCULOSIS | GLAXO GROUP LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
| EP-1954697-B1 | PERI CONDENSED TRICYCLIC COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2010-02-24 | — | — | EP | disclosed |
| US-20080280892-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
| EP-1980251-A1 | Pyrrolo[3,2,1-ij]quinoline-4-one derivatives for treating tuberculosis | GLAXO GROUP LIMITED (GB) | 2008-10-15 | — | — | EP | disclosed |
| US-20080221110-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221110-A1 | Compounds | NRDC, NISCH, MRPL21 | CTNNB1 3786/4885WNT3A 4441/4885 |
| US-20100048544-A1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE-DERIVATIVES FOR TREATING TUBERCULOSIS | NQO2, MT-ND1, SDHB | CTNNB1 3108/4885WNT3A 3564/4885 |
| US-20080280892-A1 | Compounds | NRDC, NACA, NAA50 | CTNNB1 2946/4885WNT3A 4196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.